Karuna Therapeutics KRTX Stock
Karuna Therapeutics Price Chart
Karuna Therapeutics KRTX Financial and Trading Overview
| Karuna Therapeutics stock price | 329.83 USD |
| Previous Close | 240.22 USD |
| Open | 239.5 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 234.52 - 240.46 USD |
| 52 Week Range | 101.8 - 278.25 USD |
| Volume | 419.77K USD |
| Avg. Volume | 426.29K USD |
| Market Cap | 8.93B USD |
| Beta (5Y Monthly) | 1.118069 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 275.39 USD |
KRTX Valuation Measures
| Enterprise Value | 7.53B USD |
| Trailing P/E | N/A |
| Forward P/E | -22.675856 |
| PEG Ratio (5 yr expected) | 1.13 |
| Price/Sales (ttm) | 791.09607 |
| Price/Book (mrq) | 5.9949236 |
| Enterprise Value/Revenue | 666.468 |
| Enterprise Value/EBITDA | -22.239 |
Trading Information
Karuna Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.118069 |
| 52-Week Change | 127.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 278.25 USD |
| 52 Week Low | 101.8 USD |
| 50-Day Moving Average | 212.89 USD |
| 200-Day Moving Average | 209.48 USD |
KRTX Share Statistics
| Avg. Volume (3 month) | 426.29K USD |
| Avg. Daily Volume (10-Days) | 356.96K USD |
| Shares Outstanding | 37.44M |
| Float | 35.72M |
| Short Ratio | 6.45 |
| % Held by Insiders | 5.48% |
| % Held by Institutions | 92.79% |
| Shares Short | 2.13M |
| Short % of Float | 7.03% |
| Short % of Shares Outstanding | 5.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3007.35% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.32% |
| Return on Equity (ttm) | -32.51% |
Income Statement
| Revenue (ttm) | 11.29M USD |
| Revenue Per Share (ttm) | 0.34 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 10.64M USD |
| EBITDA | -338368992 USD |
| Net Income Avi to Common (ttm) | -315692000 USD |
| Diluted EPS (ttm) | -9.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.47B USD |
| Total Cash Per Share (mrq) | 39.38 USD |
| Total Debt (mrq) | 4.76M USD |
| Total Debt/Equity (mrq) | 0.32 USD |
| Current Ratio (mrq) | 59.744 |
| Book Value Per Share (mrq) | 39.792 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -278832000 USD |
| Levered Free Cash Flow (ttm) | -162728000 USD |
Profile of Karuna Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 99 High Street |
| ZIP | 02110 |
| Phone | 857 449 2244 |
| Website | https://www.karunatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 210 |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Q&A For Karuna Therapeutics Stock
What is a current KRTX stock price?
Karuna Therapeutics KRTX stock price today per share is 329.83 USD.
How to purchase Karuna Therapeutics stock?
You can buy KRTX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Karuna Therapeutics?
The stock symbol or ticker of Karuna Therapeutics is KRTX.
Which industry does the Karuna Therapeutics company belong to?
The Karuna Therapeutics industry is Biotechnology.
How many shares does Karuna Therapeutics have in circulation?
The max supply of Karuna Therapeutics shares is 38.2M.
What is Karuna Therapeutics Price to Earnings Ratio (PE Ratio)?
Karuna Therapeutics PE Ratio is 0.00000000 now.
What was Karuna Therapeutics earnings per share over the trailing 12 months (TTM)?
Karuna Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Karuna Therapeutics company belong to?
The Karuna Therapeutics sector is Healthcare.
Karuna Therapeutics KRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1410.03 USD — |
-1.98
|
— — | 1408.92 USD — | 1440.34 USD — | — - | — — |
| Nasdaq Next Generation 100 Inde NGX | 1122.61 USD — |
-5.67
|
— — | 1122.22 USD — | 1150.94 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}